# Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

> **NCT03471650** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 150 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-DCFPyL Injection

## Key facts

- **NCT ID:** NCT03471650
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-29
- **Primary completion:** 2028-03-07
- **Final completion:** 2028-03-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- Progenics Pharmaceuticals, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471650, "Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03471650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*